A Prospective Cohort Study to Assess Body Composition as a Predictor of Outcomes in Pancreatic Cancer

Not Applicable

Recruiting

• Conditions: Pancreatic Ductal Adenocarcinoma; Cancer - Pancreatic

• Registration Number: ACTRN12616000877482
• Lead Sponsor: Monash Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Adult
-Pancreatic ductal adenocarcinoma
-Diagnosed with pancreatic cancer within the last month

Exclusion Criteria

Neuromuscular disease

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chemotherapy toxicity (occurrence of adverse event gr3 or 4), assessed by review of medical records[diagnosis, 3 months and 6 months]

Secondary Outcome Measures

Name	Time	Method
Survival (by review of medical records)[at diagnosis (baseline), 3 months 6 months];Skeletal muscle volume (measured on standard of care CT scans)[at diagnosis, 3 months & 6 months];skeletal muscle strength (peak expiratory flow + handgrip strength)[at diagnosis, 3 months and 6 months];Anorexia as measured by the Functional Assessment of Anorexia and Cachexia Therapy questionnaire [diagnosis, 3 months, 6 months]